Translarna Ex-US Sales Predict a Strong US Exondys51 Launch for Sarepta (SRPT) - Baird

November 3, 2016 7:42 AM EDT
Get Alerts SRPT Hot Sheet
Price: $36.13 -4.49%

Rating Summary:
    17 Buy, 10 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade SRPT Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Baird analyst Brian Skorney reiterated an Outperform rating and $102 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they are bullish on the Translarna Ex-US launch comparisons.

Skorney commented, "We think it is notable that Translarna put up $22M in ex-U.S. sales in its seventh quarter of launch, particularly when you consider how slow European launches typically go for these types of drugs relative to the U.S. This type of performance certainly increases our conviction that SRPT shares have recently been heading in a wildly wrong direction and expect launch numbers to correct that, driving substantial upside."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $37.39 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Hot Comments, Trader Talk

Related Entities

Robert W Baird

Add Your Comment